Products

Online Inquiry

Name

Email *

Phone *

Company/Institution

Country or Region

Quantity

Services & Products Interested *

Project Description

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

PCI-32765(Ibrutinib)

inquiry

Cat No.

CEI-0270

Description

PCI-32765(Ibrutinib) can inhibit bruton tyrosine kinase (Btk) with IC50 of 0.46 nM.

CAS No.

936563-96-1

Molecular Weight

440.5

Purity

>99%

Storage

2 years at -20centigrade Powder

Targets

Bruton tyrosine kinase (Btk)

Molecular Formula

C25H24N6O2

Chemical Name

(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one

Solubility

DMSO 88 mg/mL Water

In vitro

As a selective and irreversible Btk inhibitor, PCI-32765 can inhibit Bruton tyrosine kinase (Btk) with IC50 of 0.46 nM. As Bruton tyrosine kinase (Btk) is specifically required for BCR signaling, PCI-32765 can block BCR signaling pathway by inhibiting Bruton tyrosine kinase (Btk). In CD40 or BCR activated CLL cells, PCI-32765 can inhibit BTK tyrosine phosphorylation and also effectively abrogates downstream survival pathways activated by this kinase including ERK1/2, PI3K, and NF-kappaB. In vitro, PCI-32765 inhibited BCR-activated primary B cell proliferation with IC50 of 8 nM. PCI-32765 blocked BCR signaling in human peripheral B cells at concentrations that did not affect T cell receptor signaling. As B-cell receptor (BCR) signaling is aberrantly activated in chronic lymphocytic leukemia (CLL), PCI-32765 inhibits activation-induced proliferation of CLL cells by inhibiting BTK, and effectively blocks survival signals provided externally to CLL cells from the microenvironment including soluble factors (CD40L, BAFF, IL-6, IL-4, and TNF-alpha), fibronectin engagement, and stromal cell contact.

In vivo

In MRL-Fas(lpr) lupus model, PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease. PCI-32765 also inhibited autoantibody production and the development of kidney disease in the MRL-Fas(lpr) lupus model.